76.43
-1.57(-2.01%)
Currency In USD
| Previous Close | 78 |
| Open | 76.7 |
| Day High | 84.06 |
| Day Low | 75.71 |
| 52-Week High | 105 |
| 52-Week Low | 17.52 |
| Volume | 177,274 |
| Average Volume | 92,007 |
| Market Cap | 510.75M |
| PE | -19.9 |
| EPS | -3.84 |
| Moving Average 50 Days | 78.12 |
| Moving Average 200 Days | 47.74 |
| Change | -1.57 |
If you invested $1000 in Monopar Therapeutics Inc. (MNPR) since IPO date, it would be worth $576.83 as of November 17, 2025 at a share price of $76.43. Whereas If you bought $1000 worth of Monopar Therapeutics Inc. (MNPR) shares 5 years ago, it would be worth $3,045.02 as of November 17, 2025 at a share price of $76.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
GlobeNewswire Inc.
Nov 13, 2025 1:00 PM GMT
WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announ
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 09, 2025 2:00 PM GMT
WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presentin
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announ